Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AVITA Medical, Inc.RCEL · Entity 5905 | Chief Financial Officer | July 16, 2020 | July 21, 2020 |
| Inhibikase Therapeutics, Inc.IKT · Entity 5838 | Chief Financial Officer | January 05, 2026 | January 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AVITA Medical, Inc.
Report date July 16, 2020 · Filed July 21, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 500 |
Reported balance
After 2020-07-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-07-16 · Purchase · Acquired 300 · Balance 500 F1: Reflects 1,500 of the Issuer's CHESS Depositary Interests ("CDIs"). CDIs are units of beneficial ownership in shares of Common Stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of Common Stock and have all the rights and privileges of Common Stock. The Reporting Person purchased 1,500 CDIs, which translate into 300 shares of Common Stock as set forth above. F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from A$6.81 to A$6.83, or US$23.80 to $23.90 using the 5:1 CDI conversion ratio and the currency exchange rate as in effect on the date of the transaction. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of CDIs purchased at each separate price within the ranges set forth in this footnote to this Form 4. F3: Includes 1,500 CDIs, which translate into 300 shares of Common Stock as set forth above as well as 200 shares of previously reported Common Stock. |
| Common StockSEC Table I · non-derivative | Direct | 893 |
Reported balance
After 2020-07-17 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2020-07-17 · Purchase · Acquired 393 · Balance 893 F4: The Reporting Person purchased 1,966 CDIs, which translate into 393 shares of Common Stock as set forth above. F5: Converted from a price of A$6.5 per CDI using the 5:1 CDI conversion ratio and the currency exchange rate as in effect on the date of the transaction. F6: Includes 3,466 CDIs, which translate into 693 shares of Common Stock as set forth above as well as 200 shares of previously reported Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects 1,500 of the Issuer's CHESS Depositary Interests ("CDIs"). CDIs are units of beneficial ownership in shares of Common Stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of Common Stock and have all the rights and privileges of Common Stock. The Reporting Person purchased 1,500 CDIs, which translate into 300 shares of Common Stock as set forth above.
F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from A$6.81 to A$6.83, or US$23.80 to $23.90 using the 5:1 CDI conversion ratio and the currency exchange rate as in effect on the date of the transaction. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of CDIs purchased at each separate price within the ranges set forth in this footnote to this Form 4.
F3: Includes 1,500 CDIs, which translate into 300 shares of Common Stock as set forth above as well as 200 shares of previously reported Common Stock.
F4: The Reporting Person purchased 1,966 CDIs, which translate into 393 shares of Common Stock as set forth above.
F5: Converted from a price of A$6.5 per CDI using the 5:1 CDI conversion ratio and the currency exchange rate as in effect on the date of the transaction.
F6: Includes 3,466 CDIs, which translate into 693 shares of Common Stock as set forth above as well as 200 shares of previously reported Common Stock.
Inhibikase Therapeutics, Inc.
Report date January 05, 2026 · Filed January 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.01 · Expires 2036-01-05 | Direct | 986,319 |
Reported balance
After 2026-01-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-05 · Grant · Acquired 986,319 · Balance 986,319 F1: The shares underlying the option shall vest and become exercisable in 36 equal monthly installments commencing from January 5, 2026, subject to the Reporting Person's continued employment through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the option shall vest and become exercisable in 36 equal monthly installments commencing from January 5, 2026, subject to the Reporting Person's continued employment through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 05, 2026 Filed Jan 7, 2026 21:18 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | GrantStock Option (Right to Buy) · Derivative | 986,319 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001193125-26-006343 · ownership.xml · derivative · entry 1 McIntyre David · CIK 0001404254 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 986,319 Underlying: Common Stock · 986,319 shares Expires 2036-01-05 F1 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable in 36 equal monthly installments commencing from January 5, 2026, subject to the Reporting Person's continued employment through each such vesting date. Read SEC document |
| April 14, 2025 Filed Apr 16, 2025 20:06 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | GrantStock Option (Right to Buy) · Derivative | 1,775,539 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0000950170-25-054712 · ownership.xml · derivative · entry 1 McIntyre David · CIK 0001404254 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,775,539 Underlying: Common Stock · 1,775,539 shares Expires 2035-04-14 F1 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on April 14, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued employment on each such vesting date. Read SEC document |
| July 17, 2020 Filed Jul 21, 2020 16:18 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | PurchaseCommon Stock | 393 | $22.70 | $8,921.10 |
DisclosureSEC source: 0001209191-20-043191 · doc4.xml · nonDerivative · entry 2 McIntyre David · CIK 0001404254 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 893 F4 · shares: The Reporting Person purchased 1,966 CDIs, which translate into 393 shares of Common Stock as set forth above. F5 · price: Converted from a price of A$6.5 per CDI using the 5:1 CDI conversion ratio and the currency exchange rate as in effect on the date of the transaction. F6 · balance_after: Includes 3,466 CDIs, which translate into 693 shares of Common Stock as set forth above as well as 200 shares of previously reported Common Stock. Read SEC document |
| July 16, 2020 Filed Jul 21, 2020 16:18 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | PurchaseCommon Stock | 300 | $23.85 | $7,155.00 |
DisclosureSEC source: 0001209191-20-043191 · doc4.xml · nonDerivative · entry 1 McIntyre David · CIK 0001404254 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 F1 · shares: Reflects 1,500 of the Issuer's CHESS Depositary Interests ("CDIs"). CDIs are units of beneficial ownership in shares of Common Stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of Common Stock and have all the rights and privileges of Common Stock. The Reporting Person purchased 1,500 CDIs, which translate into 300 shares of Common Stock as set forth above. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from A$6.81 to A$6.83, or US$23.80 to $23.90 using the 5:1 CDI conversion ratio and the currency exchange rate as in effect on the date of the transaction. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of CDIs purchased at each separate price within the ranges set forth in this footnote to this Form 4. F3 · balance_after: Includes 1,500 CDIs, which translate into 300 shares of Common Stock as set forth above as well as 200 shares of previously reported Common Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.